FOSTER JAMES C sold $16.9M of CRL
FOSTER JAMES C sold 75,000 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $225.00 ($16.88M total) on 2026-06-29 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale of 75,000 shares at $225/share on 2026-06-29 under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for follow-on insider activity, but this specific disclosure is typically low-signal due to the 10b5-1 structure.
What to watch
10b5-1 plans are often set months in advance; the sale size may reflect diversification or tax planning rather than forward-looking views.
Background
The article is an SEC Form 4 insider transaction disclosure for Charles River Laboratories International, Inc. (CRL).
Ticker impact
SEC Form 4 shows director Foster James C sold 75,000 CRL shares on 2026-06-29 under a 10b5-1 plan for ~$16.9M.
Likely limited near-term impact; any effect should fade unless followed by additional disclosures.
The filing is a scheduled open-market sale with a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No sector read-across; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
A large sale can still be interpreted as confidence/valuation signal, even if 10b5-1—especially if other insiders are also selling.
Key entities
- issuerCHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Subject of the Form 4 insider transaction; director sold shares under a 10b5-1 plan.
- insiderFOSTER JAMES C
Director who executed the reported open-market sale.
